TrialPh2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
Trial details
- Registry ID
- NCT06144918
- Phase
- Phase 2
SKYE
Skye Bioscience, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye PressureNCT06144918 | SKYE | Phase 2 | Completed | 2024-02-22Actual |
| Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboNCT06577090 | SKYE | Phase 2 | Active not recruiting | 2026-11-20Estimated |
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
Trial details
- Registry ID
- NCT06577090
- Phase
- Phase 2
Latest recorded trial changes
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
NCT06577090 · Skye Bioscience, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Percent change in body weight (main study)
Measure: Nature, frequency and severity of AEs (study extension)
Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs)
+ After
Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension)
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
152 participants (planned)
+ After
136 participants (actual)
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
NCT06577090 · Skye Bioscience, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Percent change in body weight
+ After
Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs)
Planned enrollment increased by 32 participants
− Before
120 participants (planned)
+ After
152 participants (planned)
Primary completion date changed
− Before
Aug 2025
+ After
20 Nov 2026